Fludarabine phosphate inj
Products billed under this code include Fludarabine Phosphate.
Payment limit per 50 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Fludarabine Phosphate.
Payment limit per 50 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Fludarabine Phosphate | Hikma Pharmaceuticals USA Inc. | 24201-0237-01 | 1 | $177.924 |
| Fludarabine Phosphate | Sagent Pharmaceuticals | 25021-0242-02 | 1 | $177.924 |
| Fludarabine Phosphate | Actavis Pharma, Inc. | 45963-0609-55 | 1 | $177.924 |
| Fludarabine Phosphate | Areva Pharmaceuticals | 59923-0604-02 | 1 | $177.924 |
| Fludarabine Phosphate | FreseniUS Kabi USA, LLC | 63323-0192-02 | 1 | $177.924 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $177.924 | −$28.375 | 50 MG | Fludarabine phosphate inj | v1, posted September 17, 2026 |
| 3Q26 | $206.299 | −$11.427 | 50 MG | Fludarabine phosphate inj | v1, posted September 15, 2026 |
| 2Q26 | $217.726 | +$136.317 | 50 MG | Fludarabine phosphate inj | v1, posted September 15, 2026 |
| 1Q26 | $81.409 | +$13.212 | 50 MG | Fludarabine phosphate inj | v1, posted September 15, 2026 |
| 4Q25 | $68.197 | −$3.452 | 50 MG | Fludarabine phosphate inj | v1, posted September 8, 2026 |
| 3Q25 | $71.649 | +$12.12 | 50 MG | Fludarabine phosphate inj | v1, posted March 10, 2026 |
| 2Q25 | $59.529 | −$108.771 | 50 MG | Fludarabine phosphate inj | v1, posted March 10, 2026 |
| 1Q25 | $168.30 | +$34.146 | 50 MG | Fludarabine phosphate inj | v1, posted December 19, 2025 |
| 4Q24 | $134.154 | −$95.15 | 50 MG | Fludarabine phosphate inj | v1, posted June 11, 2025 |
| 3Q24 | $229.304 | +$38.409 | 50 MG | Fludarabine phosphate inj | v1, posted June 11, 2025 |
| 2Q24 | $190.895 | +$16.926 | 50 MG | Fludarabine phosphate inj | v1, posted March 11, 2025 |
| 1Q24 | $173.969 | −$326.49 | 50 MG | Fludarabine phosphate inj | v1, posted December 19, 2024 |
| 4Q23 | $500.459 | −$104.289 | 50 MG | Fludarabine phosphate inj | v1, posted October 10, 2024 |
| 3Q23 | $604.748 | +$443.002 | 50 MG | Fludarabine phosphate inj | v1, posted June 5, 2024 |
| 2Q23 | $161.746 | +$56.146 | 50 MG | Fludarabine phosphate inj | v1, posted February 23, 2024 |
| 1Q23 | $105.60 | +$13.386 | 50 MG | Fludarabine phosphate inj | v1, posted December 6, 2023 |
| 4Q22 | $92.214 | +$44.152 | 50 MG | Fludarabine phosphate inj | v1, posted June 22, 2023 |
| 3Q22 | $48.062 | −$12.125 | 50 MG | Fludarabine phosphate inj | v1, posted June 9, 2023 |
| 2Q22 | $60.187 | +$3.167 | 50 MG | Fludarabine phosphate inj | v1, posted December 14, 2022 |
| 1Q22 | $57.02 | −$12.321 | 50 MG | Fludarabine phosphate inj | v1, posted June 8, 2022 |
| 4Q21 | $69.341 | −$25.159 | 50 MG | Fludarabine phosphate inj | v1, posted June 2, 2022 |
| 3Q21 | $94.50 | +$19.324 | 50 MG | Fludarabine phosphate inj | v1, posted June 2, 2022 |
| 2Q21 | $75.176 | +$20.20 | 50 MG | Fludarabine phosphate inj | v1, posted March 1, 2022 |
| 1Q21 | $54.976 | – | 50 MG | Fludarabine phosphate inj | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.